Development of amino- and dimethylcarbamate-substituted resorcinol as programmed cell death-1 (PD-1) inhibitor

被引:18
|
作者
Liu, An [1 ]
Dong, Lei [1 ,3 ]
Wei, Xiao-Li [2 ]
Yang, Xiao-Hong [1 ]
Xiao, Jun-Hai [2 ]
Liu, Zai-Qun [4 ]
机构
[1] Jilin Univ, Sch Pharmaceut Sci, Changchun 130021, Peoples R China
[2] Beijing Inst Pharmacol & Toxicol, Lab Comp Aided Drug Design & Discovery, Beijing 100850, Peoples R China
[3] Jilin Univ, Affiliated Hosp 1, Changchun 130021, Peoples R China
[4] Jilin Univ, Coll Chem, Dept Organ Chem, Changchun 130021, Peoples R China
关键词
Programmed cell death-1 (PD-1); Inhibitor; Resorcinol; 3-Hydroxythiophenol; LUNG-CANCER; BLOCKADE; THERAPY; PATHWAY; ANTIBODIES; ANTITUMOR; SAFETY; AGENTS;
D O I
10.1016/j.ejps.2016.03.023
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Blockading the interaction of programmed death-1 (PD-1) protein with its ligands (PD-Ls, such as PD-L1) was proved to be a pathway for suppressing the development of tumors and other degradations of biological species. Thus, finding PD-1 inhibitors situated at the convergence point of drug discovery. In addition to some monoclonal antibodies applied to treat cancers clinically, the screening of organic molecules for hindering the interaction of PD-1 with PD-L1 became an efficient strategy in the development of PD-1 inhibitors. Weherein applied resorcinol and 3-hydroxythiophenol as the core to link with N, N-dimethylcarbamate and other alkyl-substituted amines to afford 13 amine-appended phenyl dimethylcarbamates (AAPDs). The test for blockading the combination of PD-1 with PD-L1 revealed that abilities of 13 AAPDs were higher than that of sulfamethizole, a successful PD-1 inhibitor. In particular, large hydrophobic substituents at amine moiety or a nitro at resorcinol skeleton enhanced the inhibitory effect of AAPD even higher than that of sulfamethoxypyridazine, another successful PD-1 inhibitor. The present results may provide valuable information for further investigation on synthetic PD-1 inhibitors. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:50 / 58
页数:9
相关论文
共 50 条
  • [21] Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer
    Umran Kucukgoz Gulec
    Emine Kilic Bagir
    Semra Paydas
    Ahmet Baris Guzel
    Derya Gumurdulu
    Mehmet Ali Vardar
    Archives of Gynecology and Obstetrics, 2019, 300 : 377 - 382
  • [22] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN TYPE 2 ENDOMETRIAL CANCER
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1127 - 1127
  • [23] Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma
    Gulec, Umran Kucukgoz
    Bagir, Emine Kilic
    Paydas, Semra
    Guzel, Ahmet Baris
    Gumurdulu, Derya
    Vardar, Mehmet Ali
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2020, 244 : 51 - 55
  • [24] Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer
    Gulec, Umran Kucukgoz
    Bagir, Emine Kilic
    Paydas, Semra
    Guzel, Ahmet Baris
    Gumurdulu, Derya
    Vardar, Mehmet Ali
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2019, 300 (02) : 377 - 382
  • [25] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN TYPE 2 ENDOMETRIAL CANCER
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 220 - 220
  • [26] Programmed Cell Death-1 (PD-1) Checkpoint Blockade in Combination With a Mammalian Target of Rapamycin Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1
    Li, Hui
    Li, Xiaoqiang
    Liu, Shuang
    Guo, Lei
    Zhang, Bo
    Zhang, Jubo
    Ye, Qinghai
    HEPATOLOGY, 2017, 66 (06) : 1920 - 1933
  • [27] Expression of programmed death-1 (PD-1) in sentinel lymph nodes of breast cancer
    Mukohara, Toru
    Tatara, Takashi
    Shimono, Yohei
    Yamasaki, Takashi
    Toyoda, Masanori
    Kiyota, Naomi
    Takao, Shintaro
    Kono, Seishi
    Kakeji, Yoshihiro
    Minami, Hironobu
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Programmed Death-1 (PD-1) Receptor/PD-1 Ligand (PD-L1) Expression in Fumarate Hydratase-Deficient Renal Cell Carcinoma
    Alaghehbandan, Reza
    Stehlik, Jan
    Trpkov, Kiril
    Magi-Galluzzi, Cristina
    Foix, Maria Pane
    Berney, Daniel
    Sibony, Mathilde
    Suster, Saul
    Agaimy, Abbas
    Montiel, Delia Perez
    Pivovarcikova, Kristyna
    Michalova, Kvetoslava
    Daum, Ondrej
    Ondic, Ondrej
    Rotterova, Pavla
    Michal, Michal
    Hes, Ondrej
    LABORATORY INVESTIGATION, 2017, 97 : 211A - 211A
  • [29] Prognostic Impact of Programmed Cell Death-1 (PD-1) and PD-Ligand 1 (PD-L1) Expression in Thymic Cancer
    Funaki, S.
    Shintani, Y.
    Ose, N.
    Kawamura, T.
    Kanzaki, R.
    Minami, M.
    Okumura, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2064 - S2065
  • [30] Programmed cell death protein 1 (PD-1) in infection
    Leth, Steffen
    Jensen-Fangel, Soren
    APMIS, 2020, 128 (02) : 177 - 187